CHRS - FDA Approval Announcement Fueling Strong Move

2023-12-27 09:25:38 ET

DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- Coherus BioSciences, Inc. (NASDAQ: CHRS) announced, after yesterday’s market close, that the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY, the company’s on-body injector (OBI) presentation of UDENYCA (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Coherus BioSciences is trading at $2.93 up $0.75 (+34.40%), on 7.4M shares traded.

Its 52-week range is $1.4301 to $10.9907. It hit a 52-week low in mid-November. It’s now trading at the lower end of a gap and, if the trading volume strengthens during the regular trading session, it looks like it could refill to the $3.50 level. It also looks like it …

The post FDA Approval Announcement Fueling Strong Move appeared first on 24/7 Market News .

For further details see: